Pressemeldinger Se alle 24 treff

PLEGRIDY™ (PEGINTERFERON BETA-1A) TWO-YEAR DATA CONFIRM MAINTENANCE OF EFFICACY AND SAFETY IN MULTIPLE SCLEROSIS PATIENTS

PLEGRIDY™ (PEGINTERFERON BETA-1A) TWO-YEAR DATA CONFIRM MAINTENANCE OF EFFICACY AND SAFETY IN MULTIPLE SCLEROSIS PATIENTS

Pressemeldinger   •   30-09-2014 10:08 CEST

– Results Presented at Joint ACTRIMS-ECTRIMS Meeting Show Patients Continuously Treated with PLEGRIDY Over Two Years Demonstrate Improvement in Clinical and MRI Outcomes –

NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CONTINUED OVER FIVE YEARS WITH TECFIDERA® (DIMETHYL FUMARATE)

NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CONTINUED OVER FIVE YEARS WITH TECFIDERA® (DIMETHYL FUMARATE)

Pressemeldinger   •   30-09-2014 10:00 CEST

– Long-term Favorable Safety Profile Sustained in Patients Treated with TECFIDERA – – Positive Clinical and MRI Outcomes in Newly Diagnosed Patients –

PLEGRIDY™ (PEGINTERFERON BETA-1A) APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

PLEGRIDY™ (PEGINTERFERON BETA-1A) APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Pressemeldinger   •   11-08-2014 14:59 CEST

– Reduces Relapses, Disability Progression, and MRI Brain Lesions, with a Favorable Safety Profile Consistent with the Established Interferon Class – – Initial Country Launches Expected to Begin in the Coming Weeks –

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

Pressemeldinger   •   17-06-2014 13:58 CEST

− DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate – − Positive Results Set Stage for Regulatory Filings –

Bilder 2 treff

Oppskaket dame

Oppskaket dame

Lisens Creative Commons navngivelse
Last ned
Størrelse

6,82 KB • 43 x 63 px

Mann på benk

Mann på benk

Lisens Creative Commons navngivelse
Last ned
Størrelse

2,27 MB • 3866 x 2577 px

Dokumenter 2 treff

Biogen Idec Pipeline

Biogen Idec Pipeline

Dokumenter   •   06-05-2011 14:31 CEST

BIIB image

BIIB image

Dokumenter   •   06-05-2011 14:31 CEST

Kontaktpersoner 1 treff

  • Pressekontakt
  • Medisinsk sjef
  • MS-nevrologi
  • glenn.mdfxdjcggtgundafapersen@biogenqdjhidhnjhecjiae.com
  • 95229513
  • 23005254
Medisinsk ansvarlig for Biogen Idec's legemiddel portefølje, klinisk forskning og regulatoriske oppgaver

You haven't completed the steps for your Hosted Newsroom

You haven't entered a correct link to your helper.html file for your Hosted Newsroom. Go to Publish and complete the steps.